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ABSTRACT: The P2Y14 receptor (P2Y14R), one of eight P2Y
G protein-coupled receptors (GPCR), is involved in
inflammatory, endocrine, and hypoxic processes and is an
attractive pharmaceutical target. The goal of this research is to
develop high-affinity P2Y14R fluorescent probes based on the
potent and highly selective antagonist 4-(4-(piperidin-4-yl)-
phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (6,
PPTN). A model of hP2Y14R based on recent hP2Y12R X-
ray structures together with simulated antagonist docking
suggested that the piperidine ring is suitable for fluorophore
conjugation while preserving affinity. Chain-elongated alkynyl
or amino derivatives of 6 for click or amide coupling were
synthesized, and their antagonist activities were measured in
hP2Y14R-expressing CHO cells. Moreover, a new Alexa Fluor 488 (AF488) containing derivative 30 (MRS4174, Ki = 80 pM)
exhibited exceptionally high affinity, as compared to 13 nM for the alkyne precursor 22. A flow cytometry assay employing 30 as
a fluorescent probe was used to quantify specific binding to P2Y14R. Known P2Y receptor ligands inhibited binding of 30 with
properties consistent with their previously established receptor selectivities and affinities. These results illustrate that potency in
this series of 2-naphthoic acid derivatives can be preserved by chain functionalization, leading to highly potent fluorescent
molecular probes for P2Y14R. Such conjugates will be useful tools in expanding the SAR of this receptor, which still lacks
chemical diversity in its collective ligands. This approach demonstrates the predictive power of GPCR homology modeling and
the relevance of newly determined X-ray structures to GPCR medicinal chemistry.
G protein-coupled receptors (GPCRs) are important cellsurface signaling proteins with characteristic seven
membrane-spanning (7TM) helices. Eight GPCRs that respond
to extracellular nucleotides comprise two subfamilies of P2Y
receptors based on sequence and functional similarity: P2Y1
receptor (P2Y1R)-like P2Y1,2,4,6,11 and P2Y12R-like P2Y12−14.
The cognate agonists of the human (h) P2Y receptors include
ADP (P2Y1, P2Y12, P2Y13), ATP (P2Y2, P2Y11), uridine-5′-
diphosphate 1 (UDP: P2Y6, P2Y14), UTP (P2Y2, P2Y4), and
uridine-5′-diphosphoglucose 2 (UDPG: P2Y14) (Chart 1).1
P2Y receptors are widely distributed, with marked expression in
a number of tissues including the central and peripheral
nervous systems, lung, kidney, intestine, spleen, platelets, and
immune cells.1
The P2Y14R is expressed on immune and epithelial cells and
is involved in inflammation and hypoxic processes.2 Activation
of P2Y14R contributes to mechanical pain hypersensitivity via
microglial cells,3 enhances the mobility of neutrophils,4 and
promotes the release of mediators from mast cells.5 Recent
studies with P2Y14R knockout mice demonstrate the value of
P2Y14R antagonism as a potential therapeutic goal for diabetes
treatment.6
Development of selective and potent agonists and antago-
nists of P2Y14R is a highly important goal given the role of this
signaling protein in health and disease. To date, the structure−
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activity relationships (SARs) of only three chemical classes have
been extensively evaluated at the P2Y14R. The first class
consists of synthetic nucleotide analogues of 2, including potent
agonists 3−5 (Chart 1).7,8 The second class is made up of
derivatives of 2-naphthoic acid, notably the highly potent and
selective antagonist 4-(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluor-
omethyl)-phenyl)-2-naphthoic acid 6 and its ester prodrug
7.9,10 The third class consists of analogues built on a
pyrido[4,3-d]pyrimidine scaffold, with compound 8 as one of
the most potent members.11 We have used the recently
reported high-resolution crystal structures of the hP2Y12R in
complex with an antagonist or full agonist12,13 to construct
homology models of the hP2Y14R for ligand docking. This
structural insight, which we show to be consistent with ligand
pharmacology, has guided our molecular design process at this
closely related receptor on the δ-branch of Family A GPCRs.
Most of the analogues of 2 are poor drug candidates due to
their low bioavailability and stability; although they could be
used in vitro, they are not optimal for in vivo or tissue-based
assays. Various representative compounds of the 2-naphthoic
acid class also display poor drug-like characteristics due to high
molecular weight and high lipophilicity.14 Nevertheless, the
chemical stability and high affinity and selectivity of 6 toward
P2Y14R over other members of the P2Y family make derivatives
of 6 potentially attractive candidates for further development of
chemical probes for this receptor.15 We propose to use the 2-
naphthoic acid series to design chain-extended analogues that
contain fluorescent and other reporter groups for receptor
detection and characterization. Such probes could be used in
place of radioligands in pharmaceutical research and drug
discovery.
■ RESULTS AND DISCUSSION
A set of functionalized analogues of 6 was designed and
prepared (Schemes 1 and 2) from the key ester intermediate
19, based on predictions from molecular modeling of modes of
receptor binding. The strategy behind the selection of these
target compounds is described in the following section.
Coupling was accomplished by click coupling of an azide and
alkyne by copper-catalyzed [2 + 3] cycloaddition16 or amide
condensation.
Molecular Modeling. To identify an energetically favorable
binding pose of 6 and to find an appropriate site for
fluorophore conjugation, we performed a series of docking
studies using homology models of P2Y14R.
12,13 Homology
models of hP2Y14R were constructed on the basis of two
Chart 1. Representative P2Y14R Agonists (1−5) and Antagonists (6−8)
Scheme 1. Synthesis of (A) N-Alkylethynyl Derivatives of 2-
Naphthoic Acid Antagonist 6, (B) ω-Ethynylalkylamido
Derivatives of 2-Naphthoic Acid Antagonist 6, (C) Terminal
Amino and Protected Amino Derivatives of 2-Naphthoic
Acid Antagonist 6, and (D) N-Methyl Analogue of 6a
aReagents and conditions for (A): (a) (1) 4-bromobutyne-1 (for 20),
5-bromopentyne-1 (for 21 and 23) or 6-bromohexyne-1 (for 22),
K2CO3, DMF, 60−70 °C; (2) LiOH (0.5 M), CH3OH, H2O (20,
46%; 22, 57%; 23, 65%). Reagents and conditions for (B): (a) (1) 4-
pentynoic acid (for 24) or 6-heptynoic acid (for 25), HATU, iPr2NEt,
DMF, 25 °C; (2) LiOH (4 M), CH3OH, H2O (24, 40%; 25, 41%).
Reagents and conditions for (C): (a) (1) tert-butyl (3-bromopropyl)-
carbamate, K2CO3, DMF, 60−70 °C; (2) LiOH (0.5 M), CH3OH,
H2O (19%); (b) HCl (3 M), THF, H2O, 25 °C (26%). Reagents and
conditions for (D): (a) CH2O (aqueous 37%), formic acid, 100 °C;
(b) LiOH (0.5 M), CH3OH, H2O (55%).
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recently solved high-resolution X-ray crystallographic structures
of P2Y12R,
12,13 which has 49% sequence identity in the 7TM
domain to P2Y14R. The P2Y12R structure was solved both in
complex with the non-nucleotide antagonist ethyl 6-(4-
((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methyl-
nicotinate (34, AZD1283)17 and with the nucleotide agonist 2-
methylthioadenosine 5′-diphosphate (35, 2-MeSADP), reveal-
ing two very distinct conformational states of the ligand binding
pocket.12,13 Two homology models of P2Y14R based on either
an agonist- or antagonist-bound structure of P2Y12R were
generated as templates and compared for docking performance.
Docking into the P2Y14R model based on the P2Y12R−34
template did not result in high-score binding poses of the
ligand, even when side chain flexibility of the receptor was
taken into account. This is likely due to the fact that
extracellular loops 1 and 2 (ECL1 and ECL2) are not resolved
in the structure of the P2Y12R−34 template, leaving the
expected binding pocket widely open and incomplete and
rendering the homology model unsuitable for docking new
ligands (see Discussion). On the other hand, flexible docking of
compound 6 into a P2Y14R model based on the P2Y12R−35
template consistently predicted a high-scoring binding pose in
which 6 fits snugly into the narrow cavity and partially overlaps
with 35 (Figure 1A). In this pose, the trifluoromethylphenyl
moiety of 6 is buried in the hydrophobic pocket closer to the
central part of the receptor delineated by residues Val99,
Asn156, His184, Ser187, Asn188, and Phe191. The carboxylate
group forms an ionic bridge between positively charged amino
groups of Lys77 (transmembrane helix 1, TM1) and Lys171
(ECL2) side chains. Most importantly, the 4-piperidylphenyl
moiety of 6 in this model points toward the extracellular
opening of the pocket so that its charged piperidine group is
accessible to solvent. Hence, we concluded that the piperidine
nitrogen in 6 is the most suitable location for attaching an
elongated chain to link a fluorophore or other reporter group or
pharmacophore. Figure 1B depicts one docked alkylated
Scheme 2. Synthesis of Fluorescent Conjugates of the 2-Naphthoic Acid P2Y14R Antagonists
a
a(A) AF488 as fluorophore. Reagents and conditions: CuSO4 (7.5% aqueous solution), sodium ascorbate (1 M aqueous solution), tBuOH, H2O, 25
°C (4%). (B) BODIPY as fluorophore. Reagents and conditions: CuSO4, sodium ascorbate, tBuOH, H2O, 25 °C (7.2%).
Figure 1. Docking of 6 and its derivatives at the hP2Y14R. (A) Predicted binding mode of the original scaffold 6. (B) Predicted binding mode of
hexyne-containing derivative 22. (C) Predicted binding mode of cyclized azaspiro[4.5]decan-5-ium product 23. The docked compounds are shown
with carbon atoms colored yellow. The hP2Y14R model, shown as gray ribbon and sticks with carbon atoms colored gray, was generated by
homology using the P2Y12R crystal structure (PDB ID 4PXZ) and extensive conformational optimization. Ionic interactions of the carboxylic group
with lysine side chains are traced as small spheres. The background part of the binding pocket is shown as a cyan surface.
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analogue of 6 (hexynyl derivative 22 shown in Figure 1 to bind
with moderately high P2Y14R affinity) as an illustration of this
concept.
The involvement of the carboxylate of 6 in strong polar
interactions within the binding site is consistent with known
SAR in this series: The inactivity of ester prodrug 7 and its
congeners is indicative of the need for a free carboxylate.14
Thus, it was reported that replacement of the carboxylate
functionality of 6 with other neutral (e.g., ester, amide) or
negatively charged (e.g., acetic acid, phosphate) moieties led to
a decrease in antagonist activity.9,14 The requirement for a free
carboxylate excluded that site from consideration as a potential
fluorophore conjugation site.
In the P2Y14R agonist series, we have already explored chain
functionalization for conjugation to larger carrier moieties with
retention or even enhancement of biological activity. In a series
of nucleotide-based agonists, conversion of the carboxylate
group of 36 (uridine-5′-diphosphoglucuronic acid) to N-alkyl
amides preserves potency of the agonist.8 Additionally,
conjugation of 36 to polyamidoamine (PAMAM) dendrimers
yielded agonists with enhanced potency, depending on the
density of pharmacophore substitution of the polymer.18
Thus, we sought to apply a functionalized congener approach
to antagonists of the P2Y14R. Subsequent SAR exploration of
the 2-naphthoic acid class of P2Y14R antagonists was performed
to find an appropriate fluorophore−pharmacophore linker.
Chemical Synthesis. The key intermediate ethyl ester
1910,14 containing a free piperidine nitrogen was prepared from
protected amine 18 as previously described (Supporting
Information Scheme 1).14,15
Intermediate 14 containing the naphthoic acid core was
prepared in four steps from 9 and 10 (Supporting Information
Scheme 1).19 In short, condensation between 9 and 10 in the
presence of sodium hydride yielded (E)-benzylidenesuccinate
11. The tertiary butyl ester of 11 was saponified, and the
resulting acid 12 was cyclized in the presence of acetic
anhydride. Acetate 13 was further hydrolyzed to provide 14.
The aryl substituents at the naphthoate present in the
structures of 6 and 19 were introduced via two consecutive
Suzuki transformations in a way similar to that previously
described (Supporting Information Scheme 1).10,15 The Suzuki
coupling between 14 and p-trifluoromethylphenylboronic acid
afforded 15. Phenol 15 was treated with triflic anhydride
followed by bis(pinacolato)diboron to obtain boronate 17. The
second Suzuki reaction between 17 and tert-butyl 4-(4-
bromophenyl)-5,6-dihydropyridine-1(2H)-carboxylate resulted
in compound 18, which contains the framework of 6.
Hydrogenation of 18 followed by carbamate cleavage afforded
desired compound 19.14
We began derivatization of 6 by alkylating the piperidine
moiety of 19 (Scheme 1). Three homologous alkyl bromides
bearing a terminal acetylene group were prepared from the
corresponding alcohols20−23 and used in alkylation to prepare
20−22. It is interesting to note that the product of alkylation of
19 with 5-bromopent-1-yne, i.e., 21, was not isolated. Instead, a
product identified as possessing the structure of 23 was
obtained. The structural assignment in the case of cyclized 5-
azaspiro[4.5]decan-5-ium product 23 was made on the basis of
the 1H NMR spectra (Supporting Information). This
cyclization was observed only during the attempted preparation
of precursor 21, containing three methylene groups adjacent to
the alkyne. The characteristic signal from the alkyne proton that
would be expected in the case of 21 was absent in the proton
NMR spectra. Additionally, two signals were found at 5.61 and
5.93 ppm, respectively, which are consistent with a 2-
methylenepyrrolidinium fragment in the context of the
structure.24,25
Acylated analogues 24 and 25 were prepared through
standard amide coupling reactions of 19 with 4-pentynoic
and 6-heptynoic acids, respectively, followed by the hydrolysis
of the ethyl ester with lithium hydroxide (Scheme 2).
Two additional N-alkyl analogues 26 and 27 were prepared
via alkylating 19 with tert-butyl (3-bromopropyl)carbamate26
followed by ester hydrolysis and carbamate cleavage. Analogue
27 contains an amino group that could be used to attach a
fluorophore through acylation reactions. Compound 26 was
included in the set of compounds as a test of how a bulky group
such as tert-butyloxycarbonyl (Boc) or potentially a fluorophore
would be tolerated in binding to the receptor.
The longest of the alkyne intermediates, 22, containing four
methylene groups, was further treated with AF488 azide 29
containing a widely used fluorophore to furnish 30 as a
fluorescent analogue of 6 (Scheme 2A). Similarly, analogue 32
was prepared by treating 22 with azide 31 carrying a boron-
dipyrromethene (BODIPY) fluorescent moiety (Scheme 2B),
which was prepared as reported.27 Compound 22 was chosen
for further modification based on the observed hypothetical
binding mode: the longer hexynyl chain reaches closer to the
extracellular entrance to the binding pocket between ECL3 and
helix VII (TM7, Figure 1B). We hypothesized that placing the
alkyne at the entrance of the pocket, distal from the core
pharmacophore binding site, would reduce the steric
interference with ligand binding when conjugated to the
fluorophore. The excitation and emission spectra of 30 and 32
show the expected maxima (30, 496 and 519 nm, respectively;
32, 626 and 642 nm, respectively) for these fluorophores
(Supporting Information).
Biological Characterization. All synthetic analogues were
evaluated functionally in Chinese hamster ovary (CHO) cells
stably expressing hP2Y14R (P2Y14R-CHO cells, Table 1).
15 The
activity of each antagonist analogue at the P2Y14R was
quantified by measuring its capacity to antagonize the agonist
action of the native agonist uridine-5′-diphosphoglucose 2.
Thus, 2-promoted inhibition of cyclic AMP accumulation was
measured in the presence of an EC80 concentration (316 nM)
Table 1. Functional Evaluation of Antagonism by the 2-




6 0.3 ± 0.1
19 120 ± 8
20 2.7 ± 1.2
22 13.0 ± 1.1
23 2.0 ± 0.2
24 6.7 ± 2.2
25 8.3 ± 1.9
26 26.0 ± 6.0
27 14.0 ± 2.4
28 7.1 ± 1.6
30 0.08 ± 0.02
32 >100
aAntagonism of the inhibition of cyclic AMP accumulation induced by
2 (316 nM) acting at the hP2Y14R in the presence of 30 μM forskolin.
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of 2 alone or in the presence of 316 nM 2 and increasing
concentrations (half-log concentrations between 10−10 and 10−5
M) of each newly synthesized molecule. IC50 values for 20 and
22−27 were determined from these inhibition curves, and Ki
values were calculated using the Cheng−Prusoff equation.28
P2Y14R antagonistic activities for the N-substituted analogues
of 6 remained in the low nanomolar range. The order of
potency for these derivatives was as follows: short alkyne 20,
cyclized 23 > N-acylpiperidines 24, 25 > long alkyne 22,
aminopropyl derivative 27 > Boc-aminopropyl derivative 26.
Ethyl ester 19 was 400-fold weaker as an antagonist than that of
free carboxylate analogue 6. This confirms the tentative
conclusion based on published work that the carboxylate is
important for recognition of the 2-naphthoic acid series of
P2Y14R antagonists.
9,14 N-Methyl derivative 28 displayed
significant receptor affinity, emphasizing that the NH of the
piperidine ring of 6 is not required for interaction with the
P2Y14R and that this N is a suitable site for chain extension.
The high affinity of the cyclized azaspiro[4.5]decan-5-ium
product 23 (Ki 2.0 nM) suggests some tolerance of steric bulk
in that region. Because the amino group of the piperidine
moiety of 23 is quaternized, it does not participate in direct H-
bonding with the receptor. Docking of this compound to
P2Y14R confirmed that the predicted orientation of the
naphthoic acid scaffold can easily accommodate a rigid spiro
ring (Figure 1C).
AF488 derivative 30 displayed enhanced potency as an
antagonist with a Ki of 80 pM, compared to 0.3 nM for 6 and
13 nM for hexynyl intermediate 22 (Figure 2). In comparison,
BODIPY derivative 32 was much weaker in its interaction with
P2Y14R. Thus, 30 was identified as a very promising candidate
fluorescent probe of P2Y14R.
AF488 conjugate 30 bound specifically to the receptor in
intact P2Y14R-CHO cells, as characterized using flow cytometry
(FCM), a technique previously used in intact cell studies with
fluorescent antagonists of other GPCRs.29 Cell labeling using
the fluorescent probe at a fixed concentration of 10 nM was
compared at two different incubation times; the level of specific
binding of 30 was greater following a 30 min incubation
compared to that at 20 min (Figure 3). A 30 min preincubation
with agonists 1, 3, or 36 at 10 μM or antagonist 6 at 10 μM
largely prevented the labeling in P2Y14R-CHO cells. The high
fraction of specific binding of 30 is evident in Figure 4, which
compares total cell fluorescence with exposure to various
combinations of ligands. The residual nonspecific binding in
the presence of 10 μM 6 is only 1.9% (20 min) or 1.1% (30
min) of the total binding of 10 nM 30 (Figure 4). Both a
P2Y1R selective antagonist N
6-methyl-2′-deoxyadenosine-3′,5′-
bisphosphate (37, MRS2179)38 and a P2Y6R selective
irreversibly binding antagonist N,N″-1,4-butanediylbis[N′-(3-
isothiocyanatophenyl)]thiourea (38, MRS 2578) failed at 10
μM to prevent binding of 30. A weak, nonselective P2R
antagonist suramin (at 10 μM) demonstrated only a minor
reduction of the level of fluorescent cell labeling. The efficiency
of inhibition of fluorescent labeling by competing ligands was in
the order 6 > 3 > 1 (Figure 4), corresponding to their order of
apparent affinities at the P2Y14R.
8,15
Use of the BODIPY conjugate 32 was compared to 30 in
experiments applying FCM. Although labeling of live P2Y14R-
CHO cells by 32 was inhibited following preincubation with
known P2Y14R ligands, it displayed significant nonspecific
binding in control CHO cells, which increased upon prolonged
incubation (Figure 3F). Thus, AF488 conjugate 30 had more
desirable characteristics than 32 as a tracer for receptor
detection and characterization and potentially in drug screening
for activity at the P2Y14R.
The predicted binding mode of 30 in the P2Y14R, as
characterized by the best conformational energy of the
complex, is presented in Figure 5. Note that despite full
flexibility of the ligand and the receptor pocket side chains the
docking pose of the 2-naphthoic acid scaffold is almost identical
to the one observed for 6, suggesting well-defined tight binding
of this chemical scaffold. Beyond this scaffold, the triazole ring
of the linker region of compound 30 interacts with the receptor
through a salt bridge to the side chain of Lys270, which may
contribute to the unusually high affinity of 30. Other
interactions contributing to the binding affinity of 30 may be
mediated by the AF488 moiety itself. Thus, the fluorophore
moiety is predicted to reach back into the shallow groove in the
ECL region of the receptor, where its carbonyl and carboxyl
moieties make polar interactions with the side chain and main
chain nitrogens of His264. One of its sulfonate groups also
forms a salt bridge to the primary amine of Lys176. Such
interactions of the AF488 substitution are unlikely to be strong
or highly specific. Nonetheless, they favorably contribute to the
binding of 30 and explain the 4-fold increase in affinity
compared to that of 6 and the 160-fold increase compared to
that of 22, which is the closest precursor of 30 studied here.
In general, additional ligand tools and molecular probes are
needed for characterizing and defining the action of P2YRs.38
Few radioligands for this family of receptors exist, and only a
few subtypes can be targeted with selective agonists and/or
antagonists.
This work is directed toward development of molecular
probes for P2Y14R that are structurally derived from a newly
reported potent and highly selective antagonist 6. In the
absence of an atomic resolution structure of P2Y14R, we
constructed homology models based on recently reported
structures of the closely related P2Y12R
12,13 and used them for
virtual docking of P2Y14R-directed antagonists. Application of
these models resulted in identification of the piperidine ring as
a likely site for chain derivatization with preservation of affinity,
and a series of analogues was synthesized to probe the effect of
distal changes on antagonist potency. The structure of the
P2Y12R template was recently solved both in complex with a
non-nucleotide antagonist 34 and with the nucleotide agonist
35, revealing drastically different conformations of the
receptor.12,13 The P2Y12R−34 antagonist complex structure
(PDB ID 4NTJ) revealed a wide open binding pocket due to
Figure 2. Concentration−response curves for 6 (blue), alkyne 22
(black), and conjugate 30 (red) in antagonism of the inhibition of
cAMP formation via human P2Y14R in P2Y14R-CHO cells.
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the unresolved ECL1 and ECL2 regions and the outward
positions of helices VI (TM6) and VII (TM7). In contrast,
TM6/TM7 are shifted toward the ligand in the agonist-bound
P2Y12R structure (PDB ID 4PXZ), and the extracellular loops
form a “lid” on top of ligand binding site participating in ligand
coordination.
Our modeling and docking results suggested that the closed
conformation of the extracellular region of P2Y14R is more
suitable for binding compound 6, providing a reasonable steric
fit for this high-affinity antagonist. The trifluoromethylphenyl
group is bound within the largely hydrophobic subpocket,
forming a π−π interaction with the Tyr102 side chain (a π−π
interaction with ligands was found in all X-ray structures of
P2Y12R). The carboxylate group forms strong charge−charge
interactions with the positively charged side chains of Lys77
and Lys171, and the piperidinyl-phenyl moiety is sandwiched
between TM7 and ECL2, with the piperidine nitrogen directed
toward the extracellular side of the receptor. In contrast, the
model based on the P2Y12R−34 template was not efficient in
docking compound 6 or its derivatives, as it did not yield any
high-scoring binding conformations. A possible explanation of
this result is that the disordered conformational state of the
extracellular region is specific to the P2Y12R complex with 34,
an antagonist that apparently pushes TM6 outward and
precludes a closed conformation of the loops.12 Moreover,
our analysis suggests that some features of the extracellular
region of the P2Y14R may favor a closed conformation of ECL2.
Thus, despite high sequence similarity and gapless alignment
between P2Y12R and P2Y14R (Supporting Information Figure
1), the ECL2 residues in P2Y14R carry only minimal
electrostatic charge (+1) compared to the highly charged
ECL2 in P2Y12R (+5 charge within a 15 residue stretch of this
loop). While the excessive positive charge of ECL2 in the
Figure 3. Binding of Alexa Fluor 488 (AF488) conjugate 30 (A−D) and boron-dipyrromethene (BODIPY) conjugate 32 (E, F) at the hP2Y14R as
characterized using FCM. Fluorescent ligands were present at 10 nM, and preincubation with competing ligands was for 30 min at 37 °C. (A) Lack
of nonspecific binding in control CHO cells of fluorescent antagonist 30. (B) Binding in P2Y14R-expressing CHO cells of fluorescent antagonist 30
alone or after preincubation with competing antagonist 6 (10 μM). (C) Binding in P2Y14R-expressing CHO cells of fluorescent agonist 30 alone or
after preincubation with competing agonist 3 (5 μM). (D) Binding in P2Y14R-expressing CHO cells of fluorescent antagonist 30 alone or after
preincubation with competing native agonist 1 (10 μM). (E) Binding in P2Y14R-expressing CHO cells of fluorescent antagonist 32 alone or after
preincubation with competing agonists 3 and antagonist 6 (all, 10 μM). (F) Nonspecific binding in control CHO cells of fluorescent antagonist 32.
Figure 4. Fluorescence ligand binding experiments using flowcy-
tometry (FCM) in P2Y14R-CHO cells with 30 after 30 min
preincubation at 37 °C with known P2Y14R agonists 1 and 3 or
P2Y14R antagonist 6. Each column shows the brightness of each
compound using 30 normalized to 100% for each time point and after
correcting the mean fluorescence intensity values for autofluorescence.
Results at 30 min expressed as mean ± SEM (n = 4) are 24.4 ± 11.5%,
1; 7.5 ± 0.8%, 3; 1.10 ± 0.06%, 6. *, P < 0.05, when compared to cells
treated with only 30. No significant difference in mean fluorescence
intensity was observed at 30 min in the presence of P2Y1R antagonist
37 (10 μM, 80.9 ± 8.6%, data not shown) or P2Y6R antagonist 38 (10
μM, 100.7 ± 10.5%, data not shown). Fluorescence in the presence of
weak, nonselective P2R antagonist suramin (10 μM) was 82.1 ± 3.6%
(data not shown).
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P2Y12R is thought to destabilize the loop in the absence of
ATP/ADP analogues, the more neutral ECL2 in P2Y14R may
favor the closed conformation even in an antagonist-bound or
apo state. Predicted binding of compound 6 may further
stabilize ECL2, since its carboxylate group forms ionic bridges
with both Lys77 in TM2 and Lys171 in ECL2 in an extensive
network of ionic interactions that also involves Lys277, Arg274,
Asp81, and Glu278 (Supporting Information Figure 2). Our
modeling therefore suggests novel insight into conformational
states of the P2Y14R that are more reminiscent of the closed,
rather than the open conformational state observed in the
crystal structure of P2Y12R.
The placement of the piperidine moiety of docked 6 in a
solvent-accessible pocket within the receptor initially led us to
hypothesize that preservation of the protonated and charged
state of this group might be important for retaining the affinity
of target molecules for P2Y14R. However, biological character-
ization of the analogues synthesized revealed no advantage in
potency for N-alkylated analogues of 6 in comparison tothat of
N-acylated derivatives.
A goal of this research is to introduce reliable probes for
P2Y14R to provide methods for fluorescent characterization of
P2Y14R both in membranes and intact cells. The derivatives of
6 were furnished with alkynyl or amino groups, suitable for
attachment of fluorescent moieties by click chemistry or amide
coupling, respectively. Compounds 20, 22, 26, and 27
displayed potencies within an order of magnitude of that of
the parent molecule 6, and these may be suitable for further
conjugation with fluorescent dyes. Thus, our results demon-
strate that P2Y14R potency can be preserved by chain
functionalization, leading to fluorescent molecular probes for
the receptor. Fluorescent ligands were reported previously for
other P2YRs (P2Y2,4,6), but these are nucleotide agonist
analogues that are subject to agonist-promoted internal-
ization.27,30 Compound 30 is the first fluorescent antagonist
probe of high affinity for a P2YR. It combines a hydrophilic
fluorophore with a hydrophobic pharmacophore and con-
sequently exhibits low nonspecific binding. The charged groups
on the AF488 moiety are predicted to interact with charged
amino acid residues on the ELs of the receptor to stabilize the
high-affinity complex. It is likely that distal interactions on the
ELs contribute to the exceptionally high affinity (80 pM) of 30.
In contrast, BODIPY conjugate 32 is much more hydrophobic
and displayed an unacceptable level of nonspecific binding in
control CHO cells and a low affinity at the P2Y14R. More
promising analogues now can be applied to the study of tissues
and cells in disease models such as human neutrophils, where
P2Y14R promotes chemotaxis,
4 or in LAD2 human mast cells,
where the receptor promotes release of inflammatory
mediators.5 In addition to well-described agonist-mediated
GPCR internalization, there are reports of antagonist-induced
internalization.39 Fortunately, no such internalization has been
observed in the FCM experiments (Figures 3A,B and 4). It
could be seen that with incubation in the presence of parent
antagonist 6 there is near complete reversal of binding of 30
(Figures 3B and 4), excluding the possibility of fluorescence
uptake through receptor internalization in the time frame of the
experiment. Additionally, the incubation of 30 with CHO cells
lacking expression of P2Y14R for up to 2 h has shown no
significant nonspecific binding (Figure 3A), thus excluding the
possibility of passive transport of 30 through the membrane.
In conclusion, we used molecular modeling based on a
closely related structural template of P2Y14R to identify the
piperidine moiety of 6 as the most structurally permissive
region of the antagonist for derivatization, with the objective of
covalent chain attachment through a tertiary amino group. The
pharmacological results for the newly synthesized compound
series were consistent with the structural insights gained from
P2Y12R-based homology modeling and docking at this closely
related receptor. The resulting P2Y14R model with its ECLs
defined conformationally allows prediction of specific inter-
actions with antagonist analogues. This approach demonstrates
the predictive power of GPCR homology modeling and the
value of applying newly determined X-ray structures to the
medicinal chemistry of GPCRs. Our results indicate that
P2Y14R potency in this series of 2-naphthoic acid derivatives
can be preserved by chain functionalization, leading to selective
fluorescent molecular probes for the receptor. Indeed, AF488
conjugate 30 displayed highly favorable properties when used
as a tracer in whole-cell binding assays of P2Y14R using FCM:
pharmacological selectivities consistent with the apparent
affinities of known P2Y ligands, unusually high receptor affinity
Figure 5. Predicted binding of compound 30 at the hP2Y14R. Compound 30 is shown as sticks with carbon atoms colored magenta. For comparison,
the original scaffold 6 (the same conformation as in Figure 1A) is shown with carbon atoms colored light yellow. Predicted polar and ionic
interactions of the triazole and AF488 fluorophore moieties of 30 with the receptor are traced by small green spheres. hP2Y14R is shown as a ribbon
and sticks with carbon atoms colored gray.
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of the tracer, and strikingly low nonspecific binding. The
measurement of precise P2Y14R selectivity and in situ labeling,
kinetics, and receptor saturation by 30 as well as development
of routine screening methods will be the subject of future
studies. Fluorescent ligand probes are of increasing interest as
pharmacological tools for characterizing GPCRs.40 Such
conjugates will be useful tools in expanding the SAR at this
receptor, which still lacks chemical diversity in its collective
ligands.
■ METHODS
Homology Modeling. Homology modeling of hP2Y14R was
performed using the recently solved high-resolution crystallographic
structures of hP2Y12R,
12,13 a closely related member of the P2YR
subfamily. Within the 7TM domain portion of the receptor, the
alignment between P2Y12R and P2Y14R sequences is fully continuous
(gapless), with sequence identity as high as 49%, which facilitated
reliable model building. The homology modeling was performed with
the ICM-Pro molecular modeling package’s build model function
using full energy-based conformational sampling and optimization of
the side chains in internal coordinates.31−33 Both the closed
conformation of the hP2Y12R extracellular region (PDB ID 4PXZ)
and the open conformation (PDB ID 4NTJ) were used to generate the
models for the docking procedure.
Docking. Compounds 6, 22, and 23 were docked into the models
of hP2Y14R using ICM-Pro molecular modeling software.
31 The ligand
and residue side chains forming the binding pocket were treated as
flexible, and their conformation was thoroughly sampled in 106 Monte
Carlo (107 for compound 30) optimization steps to global
convergence of the physics-based energy function.34 The docking
procedure was repeated in 5 independent runs from different starting
positions of the ligand outside of the pocket. Soft van der Waals
potentials and a high temperature parameter were used to facilitate
ligand sampling. The criteria for docking procedure convergence
included a high score for the predicted binding of the ligand in the
energy optimized complex (score < −30) and a consistently
reproduced docking conformations (RMSD < 1.5 Å). Note that the
hP2Y14R model based on the open receptor conformation did not
satisfy either of these criteria for docking of small compounds 6, 22,
and 23 and therefore was not used in docking of a larger compound
30. Starting positions for docking of compound 30 used optimal
docking position of compound 6, while the position of fluorophore
and linker was randomized.
Pharmacological Assays: Cell Culture and Reagents. CHO
cells stably expressing hP2Y14R were generated as previously
described,35 grown in F-12 medium with 10% FBS and 1% geneticin,
and maintained at 37 °C in 5% CO2. 3-Isobutyl-1-methylxanthine
(IBMX), forskolin, and 2 were purchased from Sigma-Aldrich.
[3H]Adenine was purchased from American Radiolabeled Chemicals
(St. Louis, MO). Geneticin, serum, and all cell culture medium were
purchased from Gibco Life Technologies.
Quantification of Cyclic AMP Accumulation. P2Y14R-CHO
cells were plated in 24-well plates approximately 24 h before the assay
at 70 000 cells per well and were labeled 2 h before the assay with 1
mCi [3H]adenine/well in 25 mM 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid (HEPES)-buffered serum-free DMEM. All assays
were performed in the presence of 200 μM IBMX, a phosphodiester-
ase inhibitor, and were initiated by the addition of 30 μM forskolin.
Tests of the antagonist activities of each of the newly synthesized
molecules were carried out using an EC80 concentration (316 nM) of
P2Y14R agonist 2 and a range of concentrations of the antagonist that
usually spanned 5 orders of magnitude. Incubations were for 15 min at
37 °C and were terminated by aspiration of medium and addition of
500 μL of ice-cold 5% trichloroacetic acid. [3H]Cyclic-AMP was
isolated by sequential Dowex and alumina chromatography as
previously described.36,37
Data Analysis. Agonist potencies (EC50 values) were obtained
from concentration−response curves by nonlinear regression analysis
using the GraphPad software package Prism. All experiments were
performed in triplicate assays and repeated at least three times. The
results are presented as mean ± SEM from multiple experiments or, in
the case of concentration−effect curves, from a single experiment
carried out with triplicate assays that were representative of results
from multiple experiments.
Cell Cultures for FCM. CHO-P2Y14R cells and wild-type CHO
cells were grown in DMEM/F12 (1:1) with 10% FBS, 50 U/mL
penicillin/streptomycin, and 2 mM L-glutamine. Cells were grown in
6-well plates (approximately 3 × 105 cells/well) and incubated at 37
°C in 5% CO2. When the cells reached 80% confluence, the medium
was replaced with fresh preheated medium. Compound 30 was added
in the presence or absence of the appropriate agonist or antagonist of
P2Y14R, and the decrease in fluorescence intensity was measured by
FCM.
Fluorescent Ligand Binding in CHO-P2Y14R Cells. CHO-
P2Y14R cells were incubated with known agonists or antagonists of
P2Y14R, such as agonists 1, 3, and 36 or antagonist 6. The cells were
preincubated for 30 min with the known agonist or antagonist at 37
°C in 5% CO2. Two different incubation times (20 and 30 min) in the
presence of fluorescent antagonist 30 were compared.
Following incubation with 30, the medium was removed, the cells
were washed three times with ice-cold DPBS, and 1 mL of 0.2% EDTA
was added to each well to detach the cells from the plate. After
detaching, 1 mL of medium was added to neutralize the EDTA, and
the cell suspension was incubated at 37 °C for 5−10 min. The cell
suspensions were transferred to 5 mL polystyrene round-bottomed BD
Falcon tubes and centrifuged for 5 min at 23 °C and 400g. After the
supernatant was discarded, the cells were washed with 3 mL of DPBS
and centrifuged again at 23 °C and 400g for 5 min. After
centrifugation, the supernatant was discarded, and the cells were
resuspended in 0.5 mL of DPBS for analysis by FCM.
FCM Analysis. The intensity of fluorescence emission of each
sample was measured using FCM. Cell suspensions were vortexed
briefly before analysis on a BD FACSCalibur flow cytometer. Samples
were maintained in the dark during the analysis to avoid photo-
bleaching. Mean fluorescent intensity was obtained in log mode using
the FL-1 channel for 30 and FL-4 channel for 32, and 10 000 events
were analyzed per sample. Data were collected and analyzed using BD
Cell Quest Pro software. Data analysis was performed with GraphPad
Prism 5 software. The mean autofluorescence of CHO cells was
measured in the absence of the fluorescent ligand. The mean
fluorescence intensity in the presence of fluorescent ligand was
corrected by subtracting the autofluorescence.
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